BRPI0908292A2 - "métodos e composições para administração oral de exenatida" - Google Patents

"métodos e composições para administração oral de exenatida"

Info

Publication number: BRPI0908292A2
Authority: BR; Brazil
Prior art keywords: exenatide; compositions; methods; oral administration; oral
Prior art date: 2008-05-05

Application number

BRPI0908292-1A

Other languages

English (en)

Inventor

Kidron

Miriam

Original Assignee

Oramed Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-05-05

Filing date

2009-05-03

Publication date

2015-08-04

2009-05-03 Application filed by Oramed Ltd filed Critical Oramed Ltd

2015-08-04 Publication of BRPI0908292A2 publication Critical patent/BRPI0908292A2/pt

2022-09-20 Publication of BRPI0908292B1 publication Critical patent/BRPI0908292B1/pt

Links

HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 title 1
108010011459 Exenatide Proteins 0.000 title 1
229960001519 exenatide Drugs 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/56—Protease inhibitors from plants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Zoology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Nutrition Science (AREA)
Botany (AREA)
Physiology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Biophysics (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Child & Adolescent Psychology (AREA)
Physical Education & Sports Medicine (AREA)
Oil, Petroleum & Natural Gas (AREA)
Rheumatology (AREA)
Molecular Biology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI0908292-1A 2008-05-05 2009-05-03 Métodos e composições para administração oral de exenatida BRPI0908292B1 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US7153808P	2008-05-05	2008-05-05
US61/071,538		2008-05-05
PCT/IL2009/000461 WO2009136392A2 (en)	2008-05-05	2009-05-03	Methods and compositions for oral administration of exenatide

Publications (2)

Publication Number	Publication Date
BRPI0908292A2 true BRPI0908292A2 (pt)	2015-08-04
BRPI0908292B1 BRPI0908292B1 (pt)	2022-09-20

Family

ID=41265104

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0908292-1A BRPI0908292B1 (pt)	2008-05-05	2009-05-03	Métodos e composições para administração oral de exenatida

Country Status (15)

Country	Link
US (4)	US20110046053A1 (pt)
EP (2)	EP2300031B1 (pt)
JP (4)	JP2011519915A (pt)
CN (2)	CN105903005A (pt)
AU (1)	AU2009245294B2 (pt)
BR (1)	BRPI0908292B1 (pt)
CA (1)	CA2723434C (pt)
DK (1)	DK2300031T3 (pt)
ES (1)	ES2645588T3 (pt)
HK (1)	HK1223558A1 (pt)
NO (1)	NO2300031T3 (pt)
NZ (1)	NZ589390A (pt)
RU (1)	RU2566063C2 (pt)
WO (1)	WO2009136392A2 (pt)
ZA (1)	ZA201008090B (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2006288703B2 (en) *	2005-09-06	2011-09-22	Oramed Pharmaceuticals, Inc.	Methods and compositions for oral administration of proteins
CA3083198A1 (en)	2008-03-26	2009-10-01	Oramed Ltd.	Methods and compositions for oral administration of proteins
EP2300031B1 (en) *	2008-05-05	2017-09-20	Oramed Ltd.	Methods and compositions for oral administration of exenatide
AU2010279575B2 (en)	2009-08-03	2016-05-05	Incube Labs, Llc	Swallowable capsule and method for stimulating incretin production within the intestinal tract
US9493477B2 (en)	2009-09-08	2016-11-15	Signature Therapeutics, Inc.	Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof
US8562589B2 (en)	2009-12-24	2013-10-22	Rani Therapeutics, Llc	Swallowable drug delivery device and method of delivery
US20110262355A1 (en)	2010-04-21	2011-10-27	Jenkins Thomas E	Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
US8809269B2 (en)	2010-12-23	2014-08-19	Rani Therapeutics, Llc	Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9629799B2 (en)	2010-12-23	2017-04-25	Rani Therapeutics, Llc	Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8980822B2 (en)	2010-12-23	2015-03-17	Rani Therapeutics, Llc	Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9283179B2 (en)	2010-12-23	2016-03-15	Rani Therapeutics, Llc	GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9259386B2 (en)	2010-12-23	2016-02-16	Rani Therapeutics, Llc	Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402807B2 (en)	2010-12-23	2016-08-02	Rani Therapeutics, Llc	Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8846040B2 (en)	2010-12-23	2014-09-30	Rani Therapeutics, Llc	Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809271B2 (en)	2010-12-23	2014-08-19	Rani Therapeutics, Llc	Therapeutic agent preparations comprising liraglutide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9861683B2 (en)	2010-12-23	2018-01-09	Rani Therapeutics, Llc	Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9415004B2 (en)	2010-12-23	2016-08-16	Rani Therapeutics, Llc	Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10639272B2 (en)	2010-12-23	2020-05-05	Rani Therapeutics, Llc	Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US8764733B2 (en)	2010-12-23	2014-07-01	Rani Therapeutics, Llc	Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8969293B2 (en)	2010-12-23	2015-03-03	Rani Therapeutics, Llc	Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9284367B2 (en)	2010-12-23	2016-03-15	Rani Therapeutics, Llc	Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402806B2 (en)	2010-12-23	2016-08-02	Rani Therapeutics, Llc	Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9149617B2 (en)	2010-12-23	2015-10-06	Rani Therapeutics, Llc	Device, system and methods for the oral delivery of therapeutic compounds
US8734429B2 (en)	2010-12-23	2014-05-27	Rani Therapeutics, Llc	Device, system and methods for the oral delivery of therapeutic compounds
WO2012096887A2 (en)	2011-01-11	2012-07-19	Signature Therapeutics, Inc.	Compositions comprising enzyme-cleavable oxycodone prodrug
US20120178813A1 (en)	2011-01-12	2012-07-12	Thetis Pharmaceuticals Llc	Lipid-lowering antidiabetic agent
US9370528B2 (en)	2011-03-02	2016-06-21	Volant Holdings Gmbh	Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis C virus infection
JP6029664B2 (ja) *	2011-06-29	2016-11-24	ラニセラピューティクス，エルエルシー	嚥下可能な薬物送達デバイスを用いる腸管の内腔へ送達するための治療剤製剤
ES2644962T3 (es) *	2012-01-03	2017-12-01	Oramed Ltd.	Cápsulas que contiene composiciones líquidas basadas en aceite de agentes terapéuticos combinados para tratar la diabetes
EP4082530B1 (en)	2012-02-01	2024-04-10	Oramed Ltd.	Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same
US8765811B2 (en)	2012-07-10	2014-07-01	Thetis Pharmaceuticals Llc	Tri-salt form of metformin
US9382187B2 (en)	2012-07-10	2016-07-05	Thetis Pharmaceuticals Llc	Tri-salt form of metformin
ITFI20120259A1 (it) *	2012-11-27	2014-05-28	Stefano Bacci	Analoghi del glucagon-like peptide (glp-1) per uso topico.
EP2941267B1 (en) *	2013-01-03	2022-11-16	Oramed Ltd.	Compositions for use in treating nafld
AU2014236559B2 (en)	2013-03-14	2020-03-12	Julie HUGHES	Cholestosome vesicles for incorporation of molecules into chylomicrons
EP2799062A1 (en) *	2013-05-03	2014-11-05	Gilberto Borges de Brito	Pharmaceutical product for inducing magnified release of endogenous gut hormones, pyy and glp-1, to a therapeutic effect on obesity and dm2
US9505709B2 (en)	2014-05-05	2016-11-29	Thetis Pharmaceuticals Llc	Compositions and methods relating to ionic salts of peptides
CA2949236C (en)	2014-05-15	2023-06-13	Incube Labs, Llc	Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
KR20170023061A (ko)	2014-06-18	2017-03-02	테티스 파마수티컬스 엘엘씨	활성제의 미네랄 아미노산 복합체
US9242008B2 (en)	2014-06-18	2016-01-26	Thetis Pharmaceuticals Llc	Mineral amino-acid complexes of fatty acids
US10265384B2 (en)	2015-01-29	2019-04-23	Novo Nordisk A/S	Tablets comprising GLP-1 agonist and enteric coating
CN104740647A (zh) *	2015-04-08	2015-07-01	东莞市麦亘生物科技有限公司	一种艾塞那肽口服制剂及其制备方法
SMT202100668T1 (it)	2015-05-22	2022-01-10	Univ Leland Stanford Junior	Trattamento dell'ipoglicemia post-bariatrica con antagonisti del glp-1
RU2702690C2 (ru) *	2015-08-13	2019-10-09	БИОЛИНГУС АйПи ЛЛСи	Способ получения продуктов, содержащих стабилизированные активные вещества, и композиций, содержащих таковые
US10653753B2 (en)	2016-03-04	2020-05-19	Eiger Biopharmaceuticals, Inc.	Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
CA3026264A1 (en)	2016-06-03	2017-12-07	Thetis Pharmaceuticals Llc	Compositions and methods relating to salts of specialized pro-resolving mediators
JP7584894B2 (ja)	2016-11-21	2024-11-18	アイガー・バイオファーマシューティカルズ・インコーポレイテッド	エキセンディン（９－３９）の緩衝製剤
US20220233487A1 (en)	2019-05-06	2022-07-28	Evonik Operations Gmbh	Preparation for use in weight management comprising omega-3 fatty acid salts and basic amino acids
CN112057619A (zh)	2019-06-10	2020-12-11	苏州兰鼎生物制药有限公司	一种具有降血糖作用的药物组合物
CA3168207A1 (en) *	2020-01-23	2021-07-29	Axcess (Uk) Ltd.	Cellular uptake
WO2021166899A1 (ja) *	2020-02-17	2021-08-26	宇部興産株式会社	インクレチン様物質と組み合わせて使用するための消化管プロテアーゼ阻害剤を含む薬剤
FR3120189B1 (fr) *	2021-03-01	2024-11-29	Farid Bennis	Composition pharmaceutique pour une administration par voie orale d’un agoniste du récepteur du GLP-1
MX2023010506A (es)	2021-03-09	2023-09-20	Ensysce Biosciences Inc	Composiciones que comprenden profarmacos de escision enzimatica y nafamostat de liberacion controlada y metodos de uso de estos.
CA3230025A1 (en)	2021-09-29	2023-04-06	Lynn Kirkpatrick	Enzyme-cleavable methadone prodrugs and methods of use thereof
WO2023249087A1 (ja) *	2022-06-24	2023-12-28	三生医薬株式会社	医薬組成物およびその製造方法
WO2025090920A1 (en) *	2023-10-25	2025-05-01	Piton Therapeutics, Inc.	Compositions and methods for treating dysfunction of glucose metabolism and/or regulation
US20250177488A1 (en) *	2023-12-04	2025-06-05	Poviva Corp	Compositions and methods for treating diabetes

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL68769A (en)	1983-05-23	1986-02-28	Hadassah Med Org	Pharmaceutical compositions containing insulin for oral administration
JPS6350793A (ja)	1986-08-20	1988-03-03	株式会社東芝	高速増殖炉の崩壊熱除去システム
US5034415A (en)	1987-08-07	1991-07-23	Century Laboratories, Inc.	Treatment of diabetes mellitus
ES2045276T3 (es)	1988-07-21	1994-01-16	Hoffmann La Roche	Preparacion de insulina
JPH02250823A (ja) *	1989-03-24	1990-10-08	Tsumura & Co	マイクロカプセル剤およびその製造方法
GB9007052D0 (en)	1990-03-29	1990-05-30	Skua Investments Ltd	Pharmaceutical formulations
US5206219A (en) *	1991-11-25	1993-04-27	Applied Analytical Industries, Inc.	Oral compositions of proteinaceous medicaments
US6692766B1 (en) *	1994-06-15	2004-02-17	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Controlled release oral drug delivery system
US5824638A (en) *	1995-05-22	1998-10-20	Shire Laboratories, Inc.	Oral insulin delivery
IL114673A (en)	1995-07-19	2000-12-06	Hadasit Med Res Service	Pharmaceutical compositions containing protein for oral administration
JPH09208485A (ja) *	1996-01-31	1997-08-12	Teijin Ltd	ペプチド・蛋白質性薬物の水難溶性組成物
DE69739172D1 (de)	1996-08-08	2009-01-29	Amylin Pharmaceuticals Inc	Regulation gastrointestinaler beweglichkeit
JPH10330287A (ja) *	1997-03-31	1998-12-15	Nippon Suisan Kaisha Ltd	多価不飽和脂肪酸からなる消化管吸収促進剤およびそれを含有する薬剤
US5975893A (en)	1997-06-20	1999-11-02	Align Technology, Inc.	Method and system for incrementally moving teeth
JP2000050793A (ja) *	1998-08-07	2000-02-22	Meiji Milk Prod Co Ltd	人工乳組成物
JP2000128805A (ja)	1998-10-27	2000-05-09	Nippon Suisan Kaisha Ltd	多価不飽和脂肪酸および高分子ゲルからなる経粘膜吸収促進剤及びそれを含有する薬剤
US6761903B2 (en)	1999-06-30	2004-07-13	Lipocine, Inc.	Clear oil-containing pharmaceutical compositions containing a therapeutic agent
JP2001240558A (ja)	2000-02-29	2001-09-04	Nippon Suisan Kaisha Ltd	多価不飽和脂肪酸を経粘膜吸収促進剤として含有する固形製剤。
US6673574B2 (en)	2000-11-30	2004-01-06	Unigene Laboratories Inc.	Oral delivery of peptides using enzyme-cleavable membrane translocators
KR20010069322A (ko)	2001-03-08	2001-07-25	서종수	휴대형정보단말기 또는 화상이동통신장치를 이용한전자경매방법
CN1160122C (zh)	2001-04-20	2004-08-04	清华大学	一种制备口服胰岛素油相制剂的方法
EP1414474A4 (en)	2001-07-18	2005-06-29	Solae Llc	PROTEIN BOWMAN BIRK HEMMER CONCENTRATE AND MANUFACTURING METHOD THEREFOR
US20030198666A1 (en)	2002-01-07	2003-10-23	Richat Abbas	Oral insulin therapy
US7767828B2 (en)	2003-11-12	2010-08-03	Phenomix Corporation	Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US20060286129A1 (en) *	2003-12-19	2006-12-21	Emisphere Technologies, Inc.	Oral GLP-1 formulations
US20050143303A1 (en)	2003-12-26	2005-06-30	Nastech Pharmaceutical Company Inc.	Intranasal administration of glucose-regulating peptides
US8076288B2 (en) *	2004-02-11	2011-12-13	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides having glucose lowering activity
WO2006097793A2 (en)	2004-04-15	2006-09-21	Chiasma, Ltd.	Compositions capable of facilitating penetration across a biological barrier
CN103223160B (zh)	2004-07-19	2015-02-18	比奥孔有限公司	胰岛素-低聚物共轭物,制剂及其用途
US20060046962A1 (en) *	2004-08-25	2006-03-02	Aegis Therapeutics Llc	Absorption enhancers for drug administration
EP1789075A4 (en) *	2004-08-25	2009-07-01	Uab Research Foundation	ABSORPTION ENHANCER FOR DRUG ADMINISTRATION
AU2006288703B2 (en)	2005-09-06	2011-09-22	Oramed Pharmaceuticals, Inc.	Methods and compositions for oral administration of proteins
US20070086972A1 (en)	2005-09-12	2007-04-19	Jacob Birnbaum	Hair growth compositions and methods for treating hair loss or related conditions
US20070077283A1 (en) *	2005-09-30	2007-04-05	Nastech Pharmaceutical Company Inc.	Method of enhancing transmucosal delivery of therapeutic compounds
CN101095942B (zh) *	2006-06-30	2011-11-16	北京民海生物科技有限公司	一种包含稳定剂的Exendin-4注射剂药物配方
CA3083198A1 (en)	2008-03-26	2009-10-01	Oramed Ltd.	Methods and compositions for oral administration of proteins
EP2300031B1 (en)	2008-05-05	2017-09-20	Oramed Ltd.	Methods and compositions for oral administration of exenatide
TWI474835B (zh)	2008-06-17	2015-03-01	Univ Indiana Res & Tech Corp	用於治療代謝病症及肥胖症之基於ｇｉｐ之混合激動劑
JP5740689B2 (ja)	2008-08-18	2015-06-24	エンテラバイオエルティーディー．	タンパク質の経口投与用の方法および組成物
ES2644962T3 (es)	2012-01-03	2017-12-01	Oramed Ltd.	Cápsulas que contiene composiciones líquidas basadas en aceite de agentes terapéuticos combinados para tratar la diabetes
EP4082530B1 (en)	2012-02-01	2024-04-10	Oramed Ltd.	Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same
EP2941267B1 (en)	2013-01-03	2022-11-16	Oramed Ltd.	Compositions for use in treating nafld

2009
- 2009-05-03 EP EP09742563.1A patent/EP2300031B1/en active Active
- 2009-05-03 EP EP17185379.9A patent/EP3275460A1/en not_active Withdrawn
- 2009-05-03 CN CN201511020513.XA patent/CN105903005A/zh active Pending
- 2009-05-03 CA CA2723434A patent/CA2723434C/en active Active
- 2009-05-03 US US12/990,097 patent/US20110046053A1/en not_active Abandoned
- 2009-05-03 CN CN2009801162547A patent/CN102026646A/zh active Pending
- 2009-05-03 RU RU2010146372/15A patent/RU2566063C2/ru active
- 2009-05-03 NO NO09742563A patent/NO2300031T3/no unknown
- 2009-05-03 ES ES09742563.1T patent/ES2645588T3/es active Active
- 2009-05-03 DK DK09742563.1T patent/DK2300031T3/en active
- 2009-05-03 WO PCT/IL2009/000461 patent/WO2009136392A2/en not_active Ceased
- 2009-05-03 NZ NZ589390A patent/NZ589390A/en unknown
- 2009-05-03 JP JP2011508050A patent/JP2011519915A/ja active Pending
- 2009-05-03 BR BRPI0908292-1A patent/BRPI0908292B1/pt active IP Right Grant
- 2009-05-03 AU AU2009245294A patent/AU2009245294B2/en active Active
2010
- 2010-11-11 ZA ZA2010/08090A patent/ZA201008090B/en unknown
2013
- 2013-04-02 US US13/855,346 patent/US10350162B2/en active Active
2014
- 2014-09-05 JP JP2014181740A patent/JP6356548B2/ja active Active
2016
- 2016-08-12 JP JP2016158435A patent/JP6379143B2/ja active Active
- 2016-10-14 HK HK16111867.9A patent/HK1223558A1/zh unknown
2018
- 2018-03-28 JP JP2018063341A patent/JP2018115204A/ja active Pending
2019
- 2019-06-10 US US16/435,854 patent/US20190314275A1/en not_active Abandoned
2021
- 2021-04-29 US US17/243,660 patent/US20210322305A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2723434C (en)	2018-01-23
JP2018115204A (ja)	2018-07-26
NO2300031T3 (pt)	2018-02-17
BRPI0908292B1 (pt)	2022-09-20
DK2300031T3 (en)	2017-10-30
JP2011519915A (ja)	2011-07-14
CA2723434A1 (en)	2009-11-12
US10350162B2 (en)	2019-07-16
US20110046053A1 (en)	2011-02-24
RU2566063C2 (ru)	2015-10-20
AU2009245294B2 (en)	2014-02-20
US20190314275A1 (en)	2019-10-17
HK1223558A1 (zh)	2017-08-04
US20210322305A1 (en)	2021-10-21
JP2017008080A (ja)	2017-01-12
EP2300031B1 (en)	2017-09-20
EP2300031A4 (en)	2012-10-24
CN105903005A (zh)	2016-08-31
WO2009136392A3 (en)	2010-03-11
EP2300031A2 (en)	2011-03-30
EP3275460A1 (en)	2018-01-31
JP6379143B2 (ja)	2018-08-22
JP2015038082A (ja)	2015-02-26
ES2645588T3 (es)	2017-12-05
WO2009136392A2 (en)	2009-11-12
NZ589390A (en)	2011-11-25
JP6356548B2 (ja)	2018-07-11
RU2010146372A (ru)	2012-06-20
AU2009245294A1 (en)	2009-11-12
CN102026646A (zh)	2011-04-20
ZA201008090B (en)	2012-08-29
US20130195939A1 (en)	2013-08-01

Legal Events

Date	Code	Title	Description
2015-12-29	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-03-13	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2019-07-02	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-10-08	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2021-06-08	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2021-09-14	B11B	Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
2021-09-21	B15G	Petition not considered as such [chapter 15.7 patent gazette]	Free format text: PETICAO NO 870210082766 DE 08/09/2021 NAO CONHECIDA EM VIRTUDE DO ART.219 (I) DA LPI, POIS FOI APRESENTADA FORA DO PRAZO (6.1 PUBLICADO NA RPI 2631 DE 08/06/2021; PRAZO DE 90 DIAS = 06/09/2021).
2022-04-05	B15V	Prolongation of time limit allowed
2022-05-17	B150	Others concerning applications: publication cancelled [chapter 15.30 patent gazette]	Free format text: ANULADA A PUBLICACAO CODIGO 15.7 NA RPI NO 2646 DE 21/09/2021 POR TER SIDO INDEVIDA.
2022-05-24	B11N	Dismissal: publication cancelled [chapter 11.14 patent gazette]	Free format text: ANULADA A PUBLICACAO CODIGO 11.2 NA RPI NO 2645 DE 14/09/2021 POR TER SIDO INDEVIDA.
2022-07-12	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2022-09-20	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/05/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

Publication	Publication Date	Title
ZA201008090B (en)	2012-08-29	Methods and compositions for oral administration of exenatide
CY2019010I2 (el)	2019-11-27	Νεες ενωσεις και συνθεσεις και μεθοδοι χρησης
HRP20190100T1 (hr)	2019-04-05	Oralne formulacije analoga citidina i postupci za njihovu upotrebu
LTPA2018014I1 (lt)	2018-12-10	Farmacinė kompozicija 514
PT2542268T (pt)	2016-11-14	Composição sólida para administração oral de corantes e utilização desta
SMT201400181B (it)	2015-01-15	Composizioni per vasocostrizione e metodi d'uso
ZA201007522B (en)	2012-12-27	Methods and compositions for oral administration of proteins
BRPI0914713A2 (pt)	2017-05-23	composição para cuidado oral
BRPI1011876A2 (pt)	2015-09-22	"composição farmacêutica estável e métodos de uso da mesma"
BRPI0808293A2 (pt)	2019-09-24	"composições para administração nasal"
PT2355851T (pt)	2018-05-23	Novos lípidos e composições para a administração de agentes terapêuticos
BRPI0913379A2 (pt)	2015-11-24	formulações farmacêuticas sólidas compreendendo bibw 2992
BRPI0812562A2 (pt)	2019-09-24	composições terapêuticas anti-cd20 e métodos
EP2316414A4 (en)	2011-09-21	HAIR CARE COMPOSITION
BRPI0810928A2 (pt)	2019-09-24	"composição farmacêutica"
BRPI0813725A2 (pt)	2014-12-30	Métodos e composições para tratamento de doenças
BRPI0923836A2 (pt)	2015-07-21	Composições farmacêuticas orais contendo opióide e métodos
LT2966175T (lt)	2019-08-26	Farmacinės kompozicijos turinčios korteksolono-17-alfa-propionato
BRPI0914300A2 (pt)	2015-10-13	composições e métodos para imunogenicidade intensificada de somatostatina
BRPI0918206A2 (pt)	2015-12-08	derivados de animoéster e composição medicinal destes
PL2026747T3 (pl)	2016-07-29	Doustne kompozycje zapewniające polepszone usuwanie przebarwień nazębnych
BRPI0821858A2 (pt)	2014-09-30	Composto, composição para cuidado oral, e, método
EP2185112A4 (en)	2012-01-18	Stabilized therapeutic compositions and formulations
BRPI0913610A2 (pt)	2015-10-20	métodos e composições para tratamento bucal
BRPI1007484A2 (pt)	2016-02-16	composição farmacêutica para administração oral